Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) EBT Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBT Margin for 2 consecutive years, with 68970.07% as the latest value for Q2 2025.

  • Quarterly EBT Margin changed N/A to 68970.07% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 40.58% through Dec 2025, changed N/A year-over-year, with the annual reading at 5.35% for FY2025, N/A changed from the prior year.
  • EBT Margin for Q2 2025 was 68970.07% at Neuphoria Therapeutics, up from 74.54% in the prior quarter.
  • The five-year high for EBT Margin was 68970.07% in Q2 2025, with the low at 291.49% in Q4 2024.